
Nearly 1 in 8 U.S. adults report having used a GLP-1 medication for weight loss. Spending on these drugs has surged past $70 billion, making GLP-1s the fastest-growing category in healthcare. But appetite suppression is only part of the story.
GLP-1 users are eating less, eating differently, and seeking foods that:
This shift is creating a new nutrition imperative—and a major opportunity for food brands and retailers who respond intelligently.
Food Is Now a Companion to GLP-1 Therapy
Clinical evidence is clear: what patients eat before, during, and after GLP-1 therapy significantly affects outcomes.
That’s where Sifter changes the game to a positive business impact. We deliver a Food Is Medicine platform that helps retailers and CPGs support GLP-1 users at the exact moment food decisions are made.
Sifter’s GLP-1-specific capabilities include:
The result: seamless movement from prescription to grocery cart.
Why This Matters for CPGs and Retailers
GLP-1 is not reducing demand for food—it’s reshaping it. This creates a strategic opening to:
Through Sifter—and in partnership with Circana’s consumer behavior intelligence—brands and retailers gain both the insight and the execution layer needed to win this shift.
GLP-1 is changing how people eat—permanently. Sifter makes that connection actionable. Let’s talk about how your brand or retail strategy can lead in the GLP-1 era.
Visit www.siftersolutions.com to request a briefing today.